source
- Samsung Bio to step into peptides in $1.8B buy for PolyPeptideSamsung Biologics is set to branch out to peptide ingredient manufacturing with plans to buy Swiss CDMO PolyPeptide for $1.8 billion in cash. The purchase, announced Monday, would be the Korean ...Endpoints · 10d ago↗ source
- Anthropic's life sciences plans: Mystery programs, Nobel hires, M&A and big ambitionA year ago, Anthropic’s life sciences plans were basically just a blog post by its CEO. In late 2024, Dario Amodei wrote a 13,000-word memo naming biology and neuroscience among his ...Endpoints · 11d ago↗ source
- Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromabScribe writes in $96M IPO: The gene editing biotech expects net proceeds of about $96 million if it prices its Nasdaq listing at $14 per share, the midpoint of the ...